This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, T. C. K. Search for Related Content PubMed PubMed Citation Articles by Chan, T. C. K.

Augmentation of 1-ß-D-Arabinofuranosylcytosine Cytotoxicity in Human Tumor Cells by Inhibiting Drug Efflux¹

Department of Physiology and Pharmacology, School of Veterinary Medicine, Purdue University, West Lafayette, Indiana 47907

Dipyridamole is a potent inhibitor of membrane nucleoside transport into mammalian cells. Since the membrane transporter mediates both the influx and the efflux of nucleosides, dipyridamole should be able to block nucleoside efflux from cells as well. In human ovarian carcinoma cells (2008) and promyelocytic leukemia cells (HL60), we observed that sequential treatment with 20 µM dipyridamole 2 h after their initial exposure to varying concentrations of 1-ß-D-arabinofuranosylcytosine (ara-C) increased the cytotoxicity of this nucleoside analogue by 100 to 300% at all drug concentrations tested. In washout experiments in which cells were exposed to radiolabeled ara-C for 2 h and reincubated in fresh medium, the presence of 20 µM dipyridamole in the reincubation medium resulted in significantly elevated levels of intracellular radioactivity at the end of a 24-h period. High performance liquid chromatography analyses of cellular nucleotide pools during this 24-h period revealed that cells treated with the sequential ara-C/dipyridamole regimen have 2- to 3-fold higher levels of ara-CTP at all time points studied. Using alkaline elution assays, we measured a 30% increase in DNA strand breaks in cells treated with ara-C followed by dipyridamole when compared to cells treated with ara-C alone, while dipyridamole alone did not produce DNA lesions. ara-C resistance in tumor cells is associated with either the natural substrates competing with ara-C for phosphorylation and incorporation into macromolecules or increased catabolism of the parent drug. Sequential exposure regimens may overcome such tumor resistance by increasing the cellular pools of ara-C and its metabolites. A second advantage to the sequential regimen is that the prolonged retention of ara-C in non-S-phase cells may improve its efficacy. The applicability of such regimens in treating human cancer awaits the results from preclinical efficacy and toxicity trials.

¹ Presented as an abstract at the American Association for Cancer Research Meeting, May 20–23, 1987, in Atlanta, GA.

² Supported by a grant from the Elsa U. Pardee Foundation and partially by grants from the Indiana Elks and the American Cancer Society through Purdue University Cancer Center.

Received 7/12/88. Revised 11/ 1/88. Revised 2/17/89. Accepted 2/21/89.

This article has been cited by other articles:

				L. P. Jordheim, E. Cros, M.-H. Gouy, C. M. Galmarini, S. Peyrottes, J. Mackey, C. Perigaud, and C. Dumontet Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug Clin. Cancer Res., August 15, 2004; 10(16): 5614 - 5621. [Abstract] [Full Text] [PDF]

				D. R. Rauchwerger, P. S. Firby, D. W. Hedley, and M. J. Moore Equilibrative-Sensitive Nucleoside Transporter and Its Role in Gemcitabine Sensitivity Cancer Res., November 1, 2000; 60(21): 6075 - 6079. [Abstract] [Full Text]

				Y.-G. Goan, B. Zhou, E. Hu, S. Mi, and Y. Yen Overexpression of Ribonucleotide Reductase as a Mechanism of Resistance to 2,2-Difluorodeoxycytidine in the Human KB Cancer Cell Line Cancer Res., September 1, 1999; 59(17): 4204 - 4207. [Abstract] [Full Text] [PDF]